82. The isolated heteromultimer according to claim **2**, wherein the heteromultimer is a bispecific antibody.

83. The isolated heteromultimer according to claim **2**, wherein the heteromultimer is a multispecific antibody.

84. A composition comprising the isolated heteromultimer according to claim **2**, and a pharmaceutically acceptable carrier.

85. A host cell comprising nucleic acid encoding the isolated heteromultimer according to claim **2**.

86. The isolated heteromultimer according claim **2**, wherein the heteromultimer is a therapeutic antibody.

87. (canceled)

88. A method of treating cancer in a patient having a cancer characterized by a cancer antigen, said method comprising administering to said patient a therapeutically effective amount of a heteromultimer of claim **86**.

89. A method of treating immune disorders in a patient having an immune disorder characterized by an immune antigen, said method comprising administering to said patient a therapeutically effective amount of a heteromultimer of claim **86**.

90. (canceled)

91. Nucleic acid encoding the isolated heteromultimer according to claim **2**.

92. The isolated heteromultimer according to claim **2**, wherein:

(a) the first Fc polypeptide comprises the amino acid modifications L351Y, F405A and Y407V and the second Fc polypeptide comprises the amino acid modifications T366L, K392L and T394W;

(b) the first Fc polypeptide comprises the amino acid modifications L351Y, F405A and Y407V and the second Fc polypeptide comprises the amino acid modifications T366L, K392M and T394W, or

(c) the first Fc polypeptide comprises the amino acid modifications L351Y, S400E, F405A and Y407V and the second Fc polypeptide comprises the amino acid modifications T366L, N390R, K392M and T394W.

93. The isolated heteromultimer according to claim **2**, wherein the variant CH2 domain comprises one or more asymmetric amino acid modifications selected from: S239D, D265S, S267D, E269K, S298A, K326E, A330L and I332E.

94. The isolated heteromultimer according to claim **93**, wherein the one or more asymmetric amino acid modifications are selected from: S239D, K326E, A330L and I332E.

95. The isolated heteromultimer according to claim **93**, wherein the one or more asymmetric amino acid modifications are selected from: S239D, D265S, E269K and I332E.

96. The isolated heteromultimer according to claim **93**, wherein the one or more asymmetric amino acid modifications are selected from: S239D, D265S and S298A.

97. The isolated heteromultimer according to claim **93**, wherein the one or more asymmetric amino acid modifications are selected from: S239D, S298A, K326E, A330L and I332E.

98. The isolated heteromultimer according to claim **93**, wherein the one or more asymmetric amino acid modifications are selected from: S239D, D265S, S298A and I332E.

99. The isolated heteromultimer according to claim **2**, wherein the heterodimer Fc region is based on an IgG1 Fc region.

100. The isolated heteromultimer according to claim **2**, wherein the heterodimer Fc region is based on a human IgG1 Fc region.

* * * * *